Dr. Gillison has received research funding from Merck.
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Supplement
You have full text access to this OnlineOpen article
HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women†
Article first published online: 3 NOV 2008
DOI: 10.1002/cncr.23764
Published 2008 by the American Cancer Society
Issue
1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Cancer
Supplement: Assessing the Burden of HPV-Associated Cancers in the United States
Volume 113, Issue Supplement 10, pages 3036–3046, 15 November 2008
Additional Information
How to Cite
Gillison, M. L., Chaturvedi, A. K. and Lowy, D. R. (2008), HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer, 113: 3036–3046. doi: 10.1002/cncr.23764
- †
The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the Centers for Disease Control and Prevention.This is a US government work and, as such, is in the public domain in the United States of America.
Publication History
- Issue published online: 3 NOV 2008
- Article first published online: 3 NOV 2008
- Manuscript Accepted: 15 JUN 2008
- Manuscript Revised: 5 JUN 2008
- Manuscript Received: 14 APR 2008
Funded by
- Cooperative Agreement. Grant Number: U50 DP424071-04
- Centers for Disease Control and Prevention (CDC)
- Abstract
- Article
- References
- Cited By
Keywords:
- human papillomavirus;
- screening;
- noncervical cancer;
- HPV vaccine
Abstract
Human papillomavirus (HPV) is a necessary cause of cervical cancer. In addition, on the basis of the fulfillment of a combination of viral as well as epidemiological criteria, it is currently accepted that a proportion of anal, oropharyngeal, vulvar, and vaginal cancers among women and anal, oropharyngeal, and penile cancers among men are etiologically related to HPV. At these noncervical sites with etiologic heterogeneity, HPV-associated cancers represent a distinct clinicopathological entity, which is generally characterized by a younger age at onset, basaloid or warty histopathology, association with sexual behavior, and better prognosis, when compared with their HPV-negative counterparts. Currently available estimates indicate that the number of HPV-associated noncervical cancers diagnosed annually in the US roughly approximates the number of cervical cancers, with an equal number of noncervical cancers among men and women. Furthermore, whereas the incidence of cervical cancers has been decreasing over time, the incidence of anal and oropharyngeal cancers, for which there are no effective or widely used screening programs, has been increasing in the US. The efficacy of HPV vaccines in preventing infection at sites other than the cervix, vagina, and vulva should, therefore, be assessed (eg, oral and anal). Given that a substantial proportion of cervical cancers (approximately 70%) and an even greater proportion of HPV-associated noncervical cancers (approximately 86% to 95%) are caused by HPV16 and 18 (HPV types that are targeted by the currently available vaccines), current HPV vaccines may hold great promise (provided equivalent efficacy at all relevant anatomic sites) in reducing the burden of HPV-associated noncervical cancers, in addition to cervical cancers. Cancer 2008;113:(10 suppl):3036–46. Published 2008 by the American Cancer Society.